Latest News - AbbVie
Top Corporates Hub
AbbVie
American Century Focused Global Growth Fund Q2 2026 Portfolio Review
13.08.2026 04:40
Key Contributors include Palo Alto Networks, ASML Holding, and Taiwan Semiconductor. Read more here.
AbbVie’s (ABBV) Botox Just Got A Step Closer To A Fifth Use
10.08.2026 16:59
AbbVie (NYSE:ABBV) just moved a step closer to expanding one of its most recognizable brands. On August 4, the FDA accepted for review a supplemental Biologics License Application for Botox Cosmetic to treat masseter muscle prominence, the jaw-muscle bulge that can give a face a wider, squarer look. If cleared, Botox Cosmetic would become the […]
Is AbbVie Stock a Buy After Posting Strong Q2 Earnings?
10.08.2026 14:04
The stock is up just 8% this year and could prove to be an undervalued buy.
Evercore ISI Group Maintains Outperform on AbbVie, Raises Price Target to $260
10.08.2026 12:02
Evercore ISI Group analyst Gavin Clark-Gartner maintains AbbVie (NYSE:ABBV) with a Outperform and raises the price target from $246 to $260.
Apogee Therapeutics Q2 EPS $(1.14) Misses $(1.05) Estimate
10.08.2026 07:22
Apogee Therapeutics (NASDAQ:APGE) reported quarterly losses of $(1.14) per share which missed the analyst consensus estimate of $(1.05) by 8.57 percent. This is a 0.88 percent decrease over losses of $(1.13) per share
REGENXBIO Q2 Earnings Call Highlights
07.08.2026 11:03
REGENXBIO (NASDAQ:RGNX) reported second-quarter 2026 progress across its late-stage gene-therapy pipeline, highlighting completed enrollment in its Duchenne muscular dystrophy confirmatory study, an agreed path to resubmit its Hunter syndrome therapy application, and the start of a pivotal diabetic
Is It Worth Investing in AbbVie (ABBV) Based on Wall Street's Bullish Views?
05.08.2026 13:30
According to the average brokerage recommendation (ABR), one should invest in AbbVie (ABBV). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Baron Capital Exits Apogee Therapeutics (APGE) Following AbbVie Buyout
05.08.2026 12:17
Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]
A New Biopharma Roadmap: Zifo's SiEE Basel Event Puts Data Before AI Hype
05.08.2026 12:00
Zifo's 2026 Scientific Informatics Experience Exchange (SiEE) in Basel convened leading experts from companies such as Roche, Bayer, Novo Nordisk, Galapagos, AbbVie, and Syngenta to tackle the industry's most pressing challenge: ensuring current digital and AI executions rest on solid data foundations while preparing for the next frontier of technological disruption.
Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence
04.08.2026 12:00
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) for BOTOX® Cosmetic (onabotulinumtoxinA) for the temporary improvement in the appearance of marked to very marked masseter muscle prominence (MMP) associated with masseter muscle activity in adults. If approved, BOTOX® Cosmetic would become the first and only neurotoxin indicated for this condition in the U.
AstraZeneca-Bristol Myers: The Floodgates for Biotech Mergers Are Open
04.08.2026 11:53
Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.
UBRELVY® (ubrogepant) Recommended for Reimbursement by Canada's Drug Agency (CDA-AMC) for Acute Migraine Treatment
04.08.2026 10:01
AbbVie (NYSE: ABBV) announced today that Canada's Drug Agency (CDA-AMC) has recommended UBRELVY® (ubrogepant) be reimbursed with conditions by public drug plans for the acute treatment of migraine, with or without aura, in adults with a history of migraine attacks with moderate to severe pain.3
AbbVie Inc. Q2 2026 Earnings Call Summary
31.07.2026 16:50
Moby summary of AbbVie Inc.'s Q2 2026 earnings call
AbbVie Q2 Earnings Call Highlights
31.07.2026 15:04
AbbVie (NYSE:ABBV) reported second-quarter 2026 results that exceeded its expectations, supported by double-digit growth in its immunology and neuroscience businesses, and raised its full-year revenue outlook by $300 million. Chairman and Chief Executive Officer Rob Michael said adjusted earnings p
AbbVie Beats but Cuts Guidance on $10.9 Billion Acquisition
31.07.2026 15:03
Revenue of $16.99 billion and adjusted EPS of $3.65 both beat estimates
AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
31.07.2026 14:00
The headline numbers for AbbVie (ABBV) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
AbbVie Q2 2026 earnings: profit forecast cut for Apogee deal
31.07.2026 13:20
The drugmaker beat second-quarter estimates on strong immunology sales but lowered its full-year adjusted earnings outlook by 14 cents a share
AbbVie’s (NYSE:ABBV) Q2 CY2026: Beats On Revenue
31.07.2026 12:59
Pharmaceutical company AbbVie (NYSE:ABBV) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 10.2% year on year to $16.99 billion. Its non-GAAP profit of $3.65 per share was 1.2% above analysts’ consensus estimates.
AbbVie (ABBV) Q2 Earnings and Revenues Beat Estimates
31.07.2026 12:55
AbbVie (ABBV) delivered earnings and revenue surprises of +0.28% and +1.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
AbbVie Bought Apogee to Strengthen Its Portfolio. Now It’s Cutting Earnings Guidance.
31.07.2026 12:31
AbbVie shares took a hit Friday after costs related to the drugmaker’s acquisition of Apogee Therapeutics forced a cut to its full-year profit outlook. Second-quarter revenue jumped 10% to nearly $17 billion, beating the $16.8 billion consensus estimate among analysts polled by FactSet. AbbVie posted adjusted earnings of $3.65 a share, narrowly ahead of Wall Street’s call for $3.60.